In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
This article was originally published in The Pink Sheet Daily
Executive Summary
Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.
You may also be interested in...
India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors
MUMBAI - GlaxoSmithKline PLC gained the top sales slot in India with Augmentin (amoxicillin/clavulanate) as a result of data analysis firm IMS Health expanding its sales audit coverage in the country
GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 1 Of 2)
Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.